Metraipolis › archive › dc_2f661bc72e61

First-in-Class Immuno-Oncology Drug APG157DS Repolarizes Innate Immune Cells and Induces Durable Remission in a Syngeneic Glioblastoma Model — Europe PMC PMID:42589344

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42589344
DOI
10.3390/ijms27156687
License (as archived)
solo-consultazione
Archived
2026-10-17T15:29:45.697Z
SHA-256 of the archived text
a5807eacce3f354c36eb5c4a3f4629e2bb14f1536bedd3811a7a173c92405bee
Stable URL of this page
https://metraipolis.com/documento/dc_2f661bc72e61

How to cite

First-in-Class Immuno-Oncology Drug APG157DS Repolarizes Innate Immune Cells and Induces Durable Remission in a Syngeneic Glioblastoma Model — Europe PMC PMID:42589344 — Europe PMC (en), https://europepmc.org/article/MED/42589344 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_2f661bc72e61 (Metraipolis archive dc_2f661bc72e61, sha256 a5807eacce3f354c36eb5c4a3f4629e2bb14f1536bedd3811a7a173c92405bee)
BibTeX
@misc{dc2f661bc72e61,
  title = {First-in-Class Immuno-Oncology Drug APG157DS Repolarizes Innate Immune Cells and Induces Durable Remission in a Syngeneic Glioblastoma Model — Europe PMC PMID:42589344},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42589344},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_2f661bc72e61; sha256 a5807eacce3f354c36eb5c4a3f4629e2bb14f1536bedd3811a7a173c92405bee},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42589344. Agents can read the archived copy with the MCP tool read_document.